| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 45.63% | Morgan Stanley | $4 → $3 | Maintains | Equal-Weight |
| 09/18/2023 | 142.72% | Stifel | $11 → $5 | Maintains | Buy |
| 09/15/2023 | 94.17% | Citigroup | $8 → $4 | Maintains | Neutral |
| 09/13/2023 | 118.45% | B of A Securities | $10 → $4.5 | Downgrades | Neutral → Underperform |
| 09/13/2023 | 94.17% | Morgan Stanley | $8.4 → $4 | Maintains | Equal-Weight |
| 09/12/2023 | 118.45% | B of A Securities | $10 → $4.5 | Downgrades | Neutral → Underperform |
| 09/12/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 09/12/2023 | 166.99% | Piper Sandler | $15 → $5.5 | Downgrades | Overweight → Neutral |
| 08/24/2023 | 307.77% | Morgan Stanley | $12 → $8.4 | Downgrades | Overweight → Equal-Weight |
| 08/21/2023 | 288.35% | Citigroup | $9 → $8 | Maintains | Neutral |
| 08/04/2023 | 482.52% | Morgan Stanley | $15 → $12 | Maintains | Overweight |
| 07/11/2023 | 336.89% | Citigroup | $15 → $9 | Downgrades | Buy → Neutral |
| 07/10/2023 | 336.89% | Citigroup | $15 → $9 | Downgrades | Buy → Neutral |
| 06/26/2023 | 531.07% | Stifel | $15 → $13 | Maintains | Buy |
| 06/12/2023 | — | Needham | Maintains | Hold | |
| 06/06/2023 | 385.44% | B of A Securities | $13 → $10 | Maintains | Buy |
| 01/06/2023 | 628.16% | Morgan Stanley | $11 → $15 | Maintains | Overweight |
| 01/06/2023 | 628.16% | Stifel | $10 → $15 | Upgrades | Hold → Buy |
| 12/12/2022 | 628.16% | Citigroup | $10 → $15 | Maintains | Buy |
| 11/11/2022 | 433.98% | Morgan Stanley | $10 → $11 | Maintains | Overweight |
| 10/11/2022 | 385.44% | Morgan Stanley | $14 → $10 | Maintains | Overweight |
| 10/04/2022 | — | Needham | Initiates Coverage On | → Hold | |
| 08/12/2022 | 579.61% | Morgan Stanley | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 628.16% | Piper Sandler | $17 → $15 | Maintains | Overweight |
| 07/26/2022 | 385.44% | Stifel | → $10 | Initiates Coverage On | → Hold |
| 07/15/2022 | 725.24% | Morgan Stanley | $18 → $17 | Maintains | Overweight |
| 05/11/2022 | 773.79% | Morgan Stanley | $27 → $18 | Maintains | Overweight |
| 05/11/2022 | 725.24% | Piper Sandler | $23 → $17 | Maintains | Overweight |
| 03/25/2022 | 1599.03% | Citigroup | $39 → $35 | Maintains | Buy |
| 02/03/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 01/07/2022 | 1210.68% | Morgan Stanley | $36 → $27 | Upgrades | Equal-Weight → Overweight |
| 08/09/2021 | 2084.47% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 08/09/2021 | 2133.01% | Citigroup | → $46 | Initiates Coverage On | → Buy |
| 08/09/2021 | 1890.29% | Morgan Stanley | → $41 | Initiates Coverage On | → Equal-Weight |
| 08/09/2021 | 2035.92% | Piper Sandler | → $44 | Initiates Coverage On | → Overweight |
What is the target price for Sight Sciences (SGHT)?
The latest price target for Sight Sciences (NASDAQ: SGHT) was reported by Morgan Stanley on November 8, 2023. The analyst firm set a price target for $3.00 expecting SGHT to rise to within 12 months (a possible 45.63% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sight Sciences (SGHT)?
The latest analyst rating for Sight Sciences (NASDAQ: SGHT) was provided by Morgan Stanley, and Sight Sciences maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Sight Sciences (SGHT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sight Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sight Sciences was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Sight Sciences (SGHT) correct?
While ratings are subjective and will change, the latest Sight Sciences (SGHT) rating was a maintained with a price target of $4.00 to $3.00. The current price Sight Sciences (SGHT) is trading at is $2.06, which is out of the analyst's predicted range.